News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ambrilia Biopharma Inc. Completes Korean Licensing Partnership with Shin Poong Pharmaceutical Co., Ltd. (019170.KS) for its Long-Acting Formulation of Octreotide


7/17/2007 8:54:05 AM

MONTREAL, QUEBEC--(MARKET WIRE)--Jul 17, 2007 -- Ambrilia Biopharma Inc. (Toronto:AMB.TO - News), a biopharmaceutical company developing novel small molecules and peptides to treat infectious diseases and cancer, announced today the signing of a licensing and distribution agreement with Shin Poong Pharmaceutical Co. of Seoul, Korea, for its sustained-release formulation of Octreotide for the treatment of acromegaly. As previously announced, Ambrilia's Octreotide is currently in Phase III clinical trials.

Read at press release

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES